As STAT3 activity is typically robust in p53 mutant cancers, whether they be p53 null or p53 missense cases, the dual targeting of both p53 and STAT3 by HO-386 provides a therapeutic advantage over other p53 reactivator agents and expands the usefulness of this agent even in p53 null cases. Here, TP53 is linked to cancer.